F7

Summary

F7 (coagulation factor VII, HGNC:3544) is a protein-coding gene on chromosome 13q34, encoding Coagulation factor VII (P08709). Initiates the extrinsic pathway of blood coagulation.

This gene encodes coagulation factor VII which is a vitamin K-dependent factor essential for hemostasis. This factor circulates in the blood in a zymogen form, and is converted to an active form by either factor IXa, factor Xa, factor XIIa, or thrombin by minor proteolysis. Upon activation of the factor VII, a heavy chain containing a catalytic domain and a light chain containing 2 EGF-like domains are generated, and two chains are held together by a disulfide bond. In the presence of factor III and calcium ions, the activated factor then further activates the coagulation cascade by converting factor IX to factor IXa and/or factor X to factor Xa. Defects in this gene can cause coagulopathy. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing to generate mature polypeptides.

Source: NCBI Gene 2155 — RefSeq curated summary.

At a glance

• Gene–disease (curated): factor VII deficiency (Definitive, ClinGen) — +1 more curated relationship
• GWAS associations: 14
• Clinical variants (ClinVar): 359 total — 25 pathogenic, 46 likely-pathogenic (top 9% of genes corpus-wide)
• GTEx eGene: eQTL in 36 tissues, sQTL in 2 (q < 0.05)
• Phenotypes (HPO): 18
• Drug target: yes — 6 curated mechanism-of-action drugs; 8 molecules with ChEMBL bioactivity
• Approved drugs (ChEMBL mechanism of action): 3 — Coagulation Factor Vii Human, Eptacog Alfa (Activated), Eptacog Beta (Activated)
• Dosage sensitivity (ClinGen): haploinsufficiency autosomal recessive, triplosensitivity unscored
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 1.11 (unconstrained)
• MANE Select transcript: NM_019616

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3544
Approved symbol	F7
Name	coagulation factor VII
Location	13q34
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000057593
Ensembl biotype	protein_coding
OMIM	613878
Entrez	2155

Gene structure

Transcript identifiers

Ensembl transcripts: 37 — 26 protein_coding, 9 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined, 1 retained_intron

MANE Select: ENST00000346342 · MANE Plus Clinical: ENST00000375581

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 2, TSL 2: 1, TSL 4: 1, TSL 5: 2

ENST00000346342, ENST00000375581, ENST00000444337, ENST00000473085, ENST00000479674, ENST00000541084, ENST00000891239, ENST00000891240, ENST00000891241, ENST00000891242, ENST00000891243, ENST00000891244, ENST00000891245, ENST00000891246, ENST00000891247, ENST00000891248, ENST00000891249, ENST00000891250, ENST00000891251, ENST00000891252, ENST00000891253, ENST00000891254, ENST00000891255, ENST00000891256, ENST00000891257, ENST00000891258, ENST00001003816, ENST00001003818, ENST00001003819, ENST00001003820, ENST00001003821, ENST00001119064, ENST00001119065, ENST00001119066, ENST00001119067, ENST00001132033, ENST00001132034

RefSeq mRNA: 3 — MANE Select: NM_019616 NM_000131, NM_001267554, NM_019616

CCDS: CCDS73602, CCDS9528, CCDS9529

Canonical transcript exons

ENST00000346342 — 8 exons

Exon	Start	End
ENSE00000687189	113117473	113117596
ENSE00000862517	113105791	113105905
ENSE00001134999	113116766	113116875
ENSE00001135032	113110690	113110850
ENSE00003582424	113115660	113115800
ENSE00003608396	113113847	113113960
ENSE00003655495	113113752	113113776
ENSE00004779919	113118413	113120685

Expression profiles

Bgee: expression breadth ubiquitous, 156 present calls, max score 97.18.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.2490 / max 66.5832, expressed in 41 samples.

Highest expression (Bgee): lobe of liver, liver, buccal mucosa cell, tendon of biceps brachii, male germ line stem cell (sensu Vertebrata) in testis.

Genetic regulation across tissues (GTEx eQTL / sQTL)

F7 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 36 tissues and its splicing (sQTL) in 2 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 38 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Skin Sun Exposed Lower leg	eqtl	1.0e-34	-0.60	13:113110921:G:A
Skin Not Sun Exposed Suprapubic	eqtl	1.6e-26	-0.73	13:113110921:G:A
Brain Frontal Cortex BA9	eqtl	1.5e-21	-0.54	13:113098517:A:G
Heart Atrial Appendage	eqtl	5.0e-20	-0.94	13:113110921:G:A
Esophagus Muscularis	eqtl	3.9e-17	-0.70	13:113110921:G:A
Adipose Subcutaneous	eqtl	5.3e-16	-0.53	13:113110921:G:A
Esophagus Gastroesophageal Junction	eqtl	6.1e-14	-0.80	13:113110921:G:A
Thyroid	eqtl	7.9e-14	-0.60	13:113110921:G:A
Cells Cultured fibroblasts	eqtl	2.9e-12	-0.47	13:113110921:G:A
Esophagus Mucosa	eqtl	5.1e-12	-0.59	13:113110921:G:A
Colon Transverse	eqtl	5.3e-12	-0.69	13:113110921:G:A
Brain Anterior cingulate cortex BA24	eqtl	8.1e-11	-0.55	13:113110921:G:A
Brain Cortex	eqtl	9.1e-11	-0.47	13:113110921:G:A
Brain Caudate basal ganglia	eqtl	3.8e-10	-0.52	13:113099001:G:A
Brain Cerebellum	eqtl	7.4e-09	+1.34	13:113098259:G:A
Stomach	eqtl	8.0e-09	-0.56	13:113105720:T:C
Adipose Visceral Omentum	eqtl	1.0e-08	-0.55	13:113110921:G:A
Breast Mammary Tissue	eqtl	1.4e-08	-0.50	13:113110921:G:A
Liver	eqtl	2.2e-08	+0.35	13:113103654:G:A
Liver	sqtl	3.5e-08	-0.74	13:113110081:G:A

FANTOM5 promoters

1 alternative TSS:

Promoter ID	TPM avg	Samples expressed
136197	0.2490	41

Top tissues by expression

showing 100 of 266 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right lobe of liver	UBERON:0001114	97.18	gold quality
liver	UBERON:0002107	95.37	gold quality
buccal mucosa cell	CL:0002336	94.87	silver quality
tendon of biceps brachii	UBERON:0008188	94.30	silver quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	84.21	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	79.05	gold quality
superficial temporal artery	UBERON:0001614	78.39	gold quality
mucosa of paranasal sinus	UBERON:0005030	77.43	gold quality
medial globus pallidus	UBERON:0002477	76.52	silver quality
gingival epithelium	UBERON:0001949	76.16	gold quality
globus pallidus	UBERON:0001875	75.29	silver quality
gingiva	UBERON:0001828	73.56	gold quality
cardia of stomach	UBERON:0001162	71.86	gold quality
ventral tegmental area	UBERON:0002691	71.42	silver quality
body of tongue	UBERON:0011876	71.15	gold quality
sperm	CL:0000019	71.14	gold quality
pericardium	UBERON:0002407	70.82	silver quality
secondary oocyte	CL:0000655	70.72	silver quality
vena cava	UBERON:0004087	70.44	gold quality
pons	UBERON:0000988	70.33	silver quality
visceral pleura	UBERON:0002401	70.15	silver quality
substantia nigra pars reticulata	UBERON:0001966	69.88	gold quality
lateral nuclear group of thalamus	UBERON:0002736	69.85	gold quality
pharyngeal mucosa	UBERON:0000355	69.68	gold quality
lateral globus pallidus	UBERON:0002476	69.67	gold quality
male germ cell	CL:0000015	69.48	gold quality
nasal cavity epithelium	UBERON:0005384	69.45	gold quality
superior vestibular nucleus	UBERON:0007227	69.28	gold quality
synovial joint	UBERON:0002217	68.93	silver quality
dorsal root ganglion	UBERON:0000044	68.80	gold quality
renal medulla	UBERON:0000362	68.64	gold quality
pancreatic ductal cell	CL:0002079	68.53	silver quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	68.51	gold quality
trachea	UBERON:0003126	68.36	gold quality
pylorus	UBERON:0001166	68.15	gold quality
epithelium of nasopharynx	UBERON:0001951	68.11	gold quality
biceps brachii	UBERON:0001507	67.80	gold quality
vastus lateralis	UBERON:0001379	67.56	gold quality
penis	UBERON:0000989	67.44	gold quality
deltoid	UBERON:0001476	67.36	silver quality
corpus epididymis	UBERON:0004359	67.08	gold quality
quadriceps femoris	UBERON:0001377	67.07	gold quality
germinal epithelium of ovary	UBERON:0001304	67.06	gold quality
cauda epididymis	UBERON:0004360	66.93	gold quality
jejunum	UBERON:0002115	66.27	silver quality
pigmented layer of retina	UBERON:0001782	66.25	gold quality
myocardium	UBERON:0002349	65.90	gold quality
left ventricle myocardium	UBERON:0006566	65.79	gold quality
Brodmann (1909) area 23	UBERON:0013554	65.72	gold quality
urethra	UBERON:0000057	65.71	gold quality
occipital lobe	UBERON:0002021	65.58	gold quality
oral cavity	UBERON:0000167	65.54	gold quality
trabecular bone tissue	UBERON:0002483	65.26	gold quality
mammalian vulva	UBERON:0000997	65.23	gold quality
parietal lobe	UBERON:0001872	65.21	gold quality
primary visual cortex	UBERON:0002436	64.94	gold quality
tibia	UBERON:0000979	64.93	gold quality
superior frontal gyrus	UBERON:0002661	64.79	gold quality
frontal cortex	UBERON:0001870	64.51	gold quality
cerebellar vermis	UBERON:0004720	64.47	gold quality
prefrontal cortex	UBERON:0000451	64.43	gold quality
postcentral gyrus	UBERON:0002581	64.19	gold quality
middle temporal gyrus	UBERON:0002771	64.08	gold quality
squamous epithelium	UBERON:0006914	64.02	gold quality
cardiac muscle of right atrium	UBERON:0003379	63.88	gold quality
layer of synovial tissue	UBERON:0007616	63.80	gold quality
upper arm skin	UBERON:0004263	63.79	gold quality
mucosa of sigmoid colon	UBERON:0004993	63.78	gold quality
tibialis anterior	UBERON:0001385	63.70	silver quality
entorhinal cortex	UBERON:0002728	63.53	gold quality
esophagus squamous epithelium	UBERON:0006920	63.50	gold quality
neocortex	UBERON:0001950	63.35	gold quality
amniotic fluid	UBERON:0000173	63.26	gold quality
cartilage tissue	UBERON:0002418	62.79	gold quality
right frontal lobe	UBERON:0002810	62.61	gold quality
jejunal mucosa	UBERON:0000399	62.59	silver quality
epithelium of esophagus	UBERON:0001976	61.81	gold quality
thymus	UBERON:0002370	61.68	gold quality
cerebral cortex	UBERON:0000956	61.38	gold quality
placenta	UBERON:0001987	61.18	gold quality
triceps brachii	UBERON:0001509	60.96	gold quality
endothelial cell	CL:0000115	60.71	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	60.54	gold quality
bronchial epithelial cell	CL:0002328	60.50	gold quality
cranial nerve II	UBERON:0000941	60.27	silver quality
cingulate cortex	UBERON:0003027	60.17	gold quality
heart right ventricle	UBERON:0002080	60.07	gold quality
right hemisphere of cerebellum	UBERON:0014890	60.05	gold quality
mammary duct	UBERON:0001765	60.02	gold quality
skin of hip	UBERON:0001554	59.98	gold quality
anterior cingulate cortex	UBERON:0009835	59.93	gold quality
palpebral conjunctiva	UBERON:0001812	59.82	gold quality
endocervix	UBERON:0000458	59.69	gold quality
bronchus	UBERON:0002185	59.69	gold quality
cerebellum	UBERON:0002037	59.65	gold quality
duodenum	UBERON:0002114	59.55	gold quality
epithelium of mammary gland	UBERON:0003244	59.47	gold quality
parotid gland	UBERON:0001831	59.33	gold quality
epithelium of bronchus	UBERON:0002031	59.31	gold quality
telencephalon	UBERON:0001893	59.26	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.79

HPA expression

RNA tissue specificity: Tissue enriched

39 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM
Liver	tissue	92.1
Postcentral gyrus	tissue	1.9
Locus coeruleus	tissue	0.9
Choroid plexus	tissue	0.8
Superior colliculi	tissue	0.8
Small intestine	tissue	0.7
Hippocampus	tissue	0.7
Testis	tissue	0.6
Nucleus accumbens	tissue	0.6
Epididymis	tissue	0.5
Duodenum	tissue	0.5
Cervix	tissue	0.4
Vagina	tissue	0.4
Fallopian tube	tissue	0.4
Pituitary gland	tissue	0.3
Ovary	tissue	0.3
Medulla oblongata	tissue	0.3
Skin 1	tissue	0.2
Retina	tissue	0.2
Parathyroid gland	tissue	0.2
Prostate	tissue	0.2
Hippocampal formation	tissue	0.2
Periaqueductal gray	tissue	0.2
Breast	tissue	0.1
Heart muscle	tissue	0.1
Adipose tissue	tissue	0.1
Esophagus	tissue	0.1
Salivary gland	tissue	0.1
Endometrium 1	tissue	0.1
Midbrain	tissue	0.1
Thalamus	tissue	0.1
Placenta	tissue	0.1
Cerebellum	tissue	0.1
Substantia nigra	tissue	0.1
Kidney	tissue	0.1
Spinal cord	tissue	0.1
Septum	tissue	0.1
Caudate putamen	tissue	0.1
Appendix	tissue	0.1

Brain sub-regions (HPA Brain Atlas): detected in 185; highest nTPM — Arcuate nucleus (1.8), Mammillary body (1.8), Precentral gyrus (1.5), Ventromedial nucleus (1.5), Inferior parietal lobule (1.4).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ATF4, CEBPB, DNMT1, EPAS1, FOS, HNF4A, PITX2, SP1

miRNA regulators (miRDB)

Targeting F7 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 57 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-3120-5P	100.00	65.56	965
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-6888-3P	99.97	65.95	1170
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-6817-3P	99.79	68.35	2126
HSA-MIR-448	99.79	72.37	2103
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-3158-5P	99.65	67.51	1763
HSA-MIR-3177-5P	99.65	70.38	1174
HSA-MIR-298	99.63	67.56	1916
HSA-MIR-3682-3P	99.58	67.63	865
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-766-3P	99.47	65.24	1811
HSA-MIR-1275	99.47	67.90	2749
HSA-MIR-653-5P	99.46	67.35	1300
HSA-MIR-548B-3P	99.38	67.26	1000
HSA-MIR-6731-5P	99.28	67.42	2375
HSA-MIR-8085	99.28	67.56	2362
HSA-MIR-10522-5P	99.26	68.50	2087
HSA-MIR-4667-3P	99.26	65.45	1608
HSA-MIR-593-3P	99.22	67.28	1327

Functional genomics

gnomAD constraint: pLI 1.11e-11, LOEUF 1.11, missense Z 0.369 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000346342 — one region, missense o/e 0.95. ClinGen dosage: haploinsufficiency 30 (autosomal recessive), triplosensitivity Not yet evaluated (unscored). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 40)

• TF-FVIIa interaction elicits intracellular signalling events implicated in sepsis, inflammation, angiogenesis, metastasis and atherosclerosis. These include the sequential activation of Src-like kinases, MAP kinases, small GTPases and calcium signalling. (PMID:11776298)
• An analog of an F7 motif, Cys-Glu-Gln-Tyr-Cys exerts its antithrombotic effect by blocking the docking of Tyr101 into a hydrophobic pocket in the catalytic domain, disrupting an essential interaction between this domain & 2d EGF-like domain of F7. (PMID:11848442)
• Factor VII activity is an independent predictor of cardiovascular mortality in elderly women of a Sicilian population. (PMID:11858478)
• Finnish carriers of the Q allele of factor Vii r/Q353 have a decreased risk of fatal myocardial infarction. (PMID:11858502)
• significant activation of FVII occurs following infusion of APOA1 into healthy male fasting subjects (PMID:11916081)
• Four novel mutations have been identified: IVS 2+1G–>C Phe 24 deletion, Leu300Pro and Arg277His. Homozygosity for the IVS2+1G–>C mutation was lethal, whereas homozygosity for the Phe 24 deletion was accompanied by a severe bleeding tendency. (PMID:11920218)
• A frequent human coagulation Factor VII mutation (A294V, c152) in loop 140s affects the interaction with activators, tissue factor and substrates. (PMID:11931672)
• The R353Q polymorphism at codon 353 and the 10 base pair insertion polymorphism of the FVII gene were associated with FVIIc and FVIIAg levels. Heterozygous individuals had lower FVIIc and FVIIAg levels than those homozygous for the common alleles. (PMID:11943935)
• TF cytoplasmic domain-independent stimulation of protein synthesis via activation of S6 kinase contributes to FVIIa effects in pathophysiology. (PMID:12019261)
• Factor VIIa induces release of von Willebrand factor from human umbilical vein endothelial cells by a tyrosine kinase dependent pathway (PMID:12083486)
• Role of zymogenicity-determining residues in cofactor interaction and macromolecular substrate recognition (PMID:12135351)
• a three-dimensional model of the ternary complex between FVIIa:TF:FIX was built using a full-space search algorithm in combination with computational graphics (PMID:12152682)
• A factor VIIa mutant with enhanced membrane affinity showed 10- to 13-fold higher activity in blood clotting in hemophiliacs. (PMID:12152685)
• FVII level is independently associated with inflammatory variables and suggest their pathophysiological link in hypercholesterolemic patients. (PMID:12208482)
• REVIEW: role of tissue factor-FVIIa complex in pathophysiological processes and effect of the inhibitors of the tissue factor:factor VII pathway (PMID:12356487)
• the inability of V154G FVIIa to accommodate an inhibitor in the active site, indicating an improperly shaped specificity pocket, would explain the low activity of the zymogen-like form of FVIIa, which is predominant in the absence of TF. (PMID:12358603)
• Two naturally occurring FVII mutations have no affinity change for TF; deficiency of coagulant activities is due to the loss of an efficient catalytic machinery in the FVII molecule. (PMID:12428089)
• factors II and X are essential for the hemostatic effects of rFVIIa, and that factors V and VIII promote these effects (PMID:12428092)
• mutagenesis of gamma-carboxyglutamic acid domain generates maximum enhancement of membrane contact site (PMID:12506121)
• The finding of FVII synthesis outside the liver–in normal and atherosclerotic vessels as well as smooth muscle cells, fibroblasts, and keratinocytes in vitro–may be indicative of other cellular functions for this coagulation protein. (PMID:12524237)
• 2 homozygous nucleotide substitutions were identified in the F7 gene: a IVS7+2T>G transversion involving the IVS7 donor splice site, followed by a mutation at nucleotide 10588 that would result in a missense variation (Arg224Gln). (PMID:12676783)
• FVIIa binding to tissue factor provided protection against apoptosis induced by growth factor deprivation, primarily through activation of PI3-kinase/Akt pathway, and to a lesser extent, p44/42 MAPK pathway (PMID:12738672)
• the factor VII R353 allele is associated with lower concentrations of plasma apolipoprotein B levels (PMID:12851844)
• the 4G/4G-PAI-1 genotype might be a protective factor against atherothrombotic cerebral infarction (ACI), whereas the factor V point mutation (1691G-A) and the factor VII Arg/Gln353 gene polymorphism have not proved to be risk factors for ACI (PMID:12859287)
• ARP1 interacted with two regions of the FVII 5’ flanking region, the hepatic nuclear factor 4 binding region and the nuclear hormone response region, indicating a role for ARP1 in transcriptional modulation of the FVII gene. (PMID:12871323)
• p21Ras activation is instrumental in FVIIa signal transduction and the FVIIa-dependent activation of p21Ras involves either PKC or Src-dependent mechanisms, depending on the cell type investigated. (PMID:12871370)
• Presence of the silent dimorphism H115H, the polymorphism R353Q and the mutation A294V. (PMID:12888866)
• Double heterozygous mutations coding the same amino acid of F VII were found in a pedigree with hereditary coagulation factor VII deficiency. (PMID:12903033)
• Factor Xa and thrombin, but not factor VIIa, induce expression of MCP-1, IL-8, IL-6 and VEGF, and expression of receptors implicated in signaling by these coagulation factors PAR-1, PAR-2 and PAR-3 in lung and dermal fibroblasts (PMID:12941034)
• plasma FVII with the promoter haplotype -670C/-630G/402A is related to increased coagulant activity, risk of an initial coronary event, and reporter gene expression (PMID:14521602)
• factor VIIa has a role in aggregation of alphaIIbbeta3-deficient platelets (PMID:14592825)
• the 60s loop of human coagulation factor VII has a role in interdomain crosstalk (PMID:14691565)
• model characterizes likely enzyme-binding exosites on FVIIa and Xa that may be involved in the ternary complex (sTF-VIIa-Xa) formation and the membrane binding region of the ternary complex. (PMID:14750502)
• The proteolytic domains of both VII and VIIa seem to interact with the same surface on thromboplastin (TF) with nearly identical residue energetics; therefore, zymogen VII can readily adopt a VIIa-like conformation required for binding to TF. (PMID:14756558)
• FVIIa induces cell survival through STAT5-dependent Bcl(XL) production and Jak2-dependent activation of PKB. TF/FVIIa-signal transduction is dependent on G12/G13 class G proteins. (PMID:15016732)
• an epidemiologic study revealed Plasma FVIIa concentrations were influenced by R353Q polymorphism, and the Q allele may be protective against premature myocardial infarction (PMID:15170085)
• Binding of FVIIa to TF on the surface of SMCs induces proliferation via a coagulation-independent mechanism and possibly indicates a new link between coagulation, inflammation, and atherosclerosis. (PMID:15173027)
• TF/FVIIa complex up-regulates the transcription of u-PAR in human ovarian cancer cells. (PMID:15182581)
• EGFR, PYK2, Yes, and SHP-2 are involved in transduction of the TF/FVIIa signal possibly via transactivation of the EGF receptor. (PMID:15213840)
• Factor VIIa has a role in mediating tenase function on activated platelets under flow (PMID:15304047)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	f7	ENSDARG00000034862
danio_rerio	f7i	ENSDARG00000075827
mus_musculus	F7	ENSMUSG00000031443
rattus_norvegicus	F7	ENSRNOG00000032737

Paralogs (16): F11 (ENSG00000088926), F9 (ENSG00000101981), HGFAC (ENSG00000109758), F10 (ENSG00000126218), KLK10 (ENSG00000129451), F12 (ENSG00000131187), C1RL (ENSG00000139178), C1R (ENSG00000159403), KLKB1 (ENSG00000164344), C1S (ENSG00000182326), PRSS55 (ENSG00000184647), CFD (ENSG00000197766), CFI (ENSG00000205403), PRSS51 (ENSG00000253649), HP (ENSG00000257017), HPR (ENSG00000261701)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:109325) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 15 distinct phenotype terms.

Mouse phenotype (MP)	Records
abnormal snout morphology	1
internal hemorrhage	1
premature death	1
abnormal blood coagulation	1
cardiac fibrosis	1
abnormal bone structure	1
decreased lean body mass	1
abnormal circulating protein level	1
heart hemorrhage	1
increased total body fat amount	1
decreased bone mineral content	1
neonatal lethality, incomplete penetrance	1
preweaning lethality, incomplete penetrance	1
increased prothrombin time	1
increased partial thromboplastin time	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Pan troglodytes	Q95ND7	99.8%	Diamond
Pongo abelii	Q5RCB6	99.5%	Diamond
Tropidechis carinatus	P81428	99.3%	Diamond
Notechis scutatus scutatus	P82807	99.3%	Diamond
Pan paniscus	Q2F9P4	98.7%	Diamond
Hoplocephalus stephensii	P83370	97.6%	Diamond
Bos taurus	P00741	96.8%	Diamond
Ovis aries	P16291	96.8%	Diamond
Macaca mulatta	Q28520	96.0%	Diamond
Oxyuranus microlepidotus	Q58L95	95.1%	Diamond
Oxyuranus scutellatus	Q58L96	95.1%	Diamond
Pseudonaja textilis	Q1L659	93.6%	Diamond
Capra hircus	Q28315	92.7%	Diamond
Cryptophis nigrescens	B5G6G5	89.2%	Diamond
Canis lupus familiaris	P19540	88.5%	Diamond
Felis catus	Q6SA95	88.5%	Diamond
Oryctolagus cuniculus	Q28661	86.3%	Diamond
Sus scrofa	P16293	86.1%	Diamond
Pseudechis porphyriacus	Q58L93	86.1%	Diamond
Demansia vestigiata	A6MFK7	85.8%	Diamond
Acropora millepora	B8VIV4	85.1%	Diamond
Equus caballus	Q28380	84.7%	Diamond
Macaca nemestrina	Q28858	79.4%	Diamond
Anopheles gambiae	P35040	76.9%	Diamond
Cavia porcellus	P16295	75.8%	Diamond
Strongylocentrotus purpuratus	P49013	74.9%	Diamond
Bombus ignitus	B5U2W0	67.2%	Diamond
Gallus gallus	Q804X6	58.1%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
ATP11A	protein-coding	23250
MCF2L	protein-coding	23263
F10-AS2	protein-coding	102724474
F10-AS1	ncRNA	104413892
F10	protein-coding	2159
MCF2L-AS1	ncRNA	100289410

Protein

Protein identifiers

Coagulation factor VII — P08709 (reviewed: P08709)

Alternative names: Proconvertin, Serum prothrombin conversion accelerator

All UniProt accessions (3): P08709, E9PH36, F5H8B0

UniProt curated annotations — full annotation on UniProt →

Function. Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X to factor Xa by limited proteolysis. Factor VIIa also converts factor IX to factor IXa in the presence of tissue factor and calcium.

Subunit / interactions. Heterodimer of a light chain and a heavy chain linked by a disulfide bond. Interacts (activated) with iripin-8, a serine protease inhibitor from Ixodes ricinus saliva.

Subcellular location. Secreted.

Tissue specificity. Plasma.

Post-translational modifications. The vitamin K-dependent, enzymatic carboxylation of some glutamate residues allows the modified protein to bind calcium. The iron and 2-oxoglutarate dependent 3-hydroxylation of aspartate and asparagine is (R) stereospecific within EGF domains. O- and N-glycosylated. N-glycosylation at Asn-205 occurs cotranslationally and is mediated by STT3A-containing complexes, while glycosylation at Asn-382 is post-translational and is mediated STT3B-containing complexes before folding. O-fucosylated by POFUT1 on a conserved serine or threonine residue found in the consensus sequence C2-X(4,5)-[S/T]-C3 of EGF domains, where C2 and C3 are the second and third conserved cysteines. Can be either O-glucosylated or O-xylosylated at Ser-112 by POGLUT1 in vitro.

Disease relevance. Factor VII deficiency (FA7D) [MIM:227500] A hemorrhagic disease with variable presentation. The clinical picture can be very severe, with the early occurrence of intracerebral hemorrhages or repeated hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages (epistaxis, menorrhagia) or hemorrhages provoked by a surgical intervention. Finally, numerous subjects are completely asymptomatic despite very low factor VII levels. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the peptidase S1 family.

Isoforms (2)

UniProt ID	Names	Canonical?
P08709-1	A	yes
P08709-2	B

RefSeq proteins (3): NP_000122, NP_001254483, NP_062562* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000152	EGF-type_Asp/Asn_hydroxyl_site	PTM
IPR000294	GLA_domain	Domain
IPR000742	EGF	Domain
IPR001254	Trypsin_dom	Domain
IPR001314	Peptidase_S1A	Family
IPR001881	EGF-like_Ca-bd_dom	Domain
IPR009003	Peptidase_S1_PA	Homologous_superfamily
IPR012224	Pept_S1A_FX	Family
IPR017857	Coagulation_fac-like_Gla_dom	Homologous_superfamily
IPR018097	EGF_Ca-bd_CS	Conserved_site
IPR018114	TRYPSIN_HIS	Active_site
IPR033116	TRYPSIN_SER	Active_site
IPR035972	GLA-like_dom_SF	Homologous_superfamily
IPR043504
IPR050442	Peptidase_S1_coag_factors	Family

Pfam: PF00008, PF00089, PF00594, PF14670

Enzyme classification (BRENDA)

• EC 3.4.21.21 — coagulation factor VIIa (BRENDA: 5 organisms, 78 substrates, 228 inhibitors, 104 Km, 93 kcat entries)

Substrate kinetics (BRENDA)

9 substrates with measured Km, best-characterized 9. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
FACTOR X	—	48
N-METHYLSULFONYL-D-PHE-GLY-ARG-P-NITROANILIDE	0.8–50	17
D-ILE-PRO-ARG-P-NITROANILIDE	0.85–10.4	14
D-ILE-PRO-ARG-4-NITROANILIDE	1.2–14	10
H-D-ISOLEUCYL-L-PROLYL-ARGININE-P-NITROANILIDE	1.5–9.8	8
BENZYLOXYCARBONYL-ARG-P-NITROBENZYL ESTER	0.19	1
METHANESULFONYL-D-CYCLOHEXYLALANYL-BUTYL-ARGININ	0.67	1
S-2288	11.8	1
SPECTROZYME FVIIA	0.67	1

UniProt features (222 total): sequence variant 122, strand 26, helix 21, disulfide bond 12, modified residue 11, turn 8, glycosylation site 5, domain 4, active site 3, site 2, mutagenesis site 2, chain 2, signal peptide 1, propeptide 1, binding site 1, splice variant 1

Structure

Experimental structures (PDB)

showing 30 of 114 structures by resolution:

PDB	Title	Method	Resolution (Å)
6R2W	Crystal structure of the super-active FVIIa variant VYT in complex with tissue factor	X-RAY DIFFRACTION	1.25
5PAG	Crystal Structure of Factor VIIa in complex with …	X-RAY DIFFRACTION	1.36
5PAX	Crystal Structure of Factor VIIa in complex with …	X-RAY DIFFRACTION	1.36
4YLQ	Crystal Structure of a FVIIa-Trypsin Chimera (FT) in Complex with Soluble Tissue Factor	X-RAY DIFFRACTION	1.4
5PAO	Crystal Structure of Factor VIIa in complex with …	X-RAY DIFFRACTION	1.4
5PAV	Crystal Structure of Factor VIIa in complex with …	X-RAY DIFFRACTION	1.4
5L0S	human POGLUT1 in complex with Factor VII EGF1 and UDP	X-RAY DIFFRACTION	1.45
5PAE	Crystal Structure of Factor VIIa in complex with …	X-RAY DIFFRACTION	1.45
5PB2	Crystal Structure of Factor VIIa in complex with …	X-RAY DIFFRACTION	1.45
5PAS	Crystal Structure of Factor VIIa in complex with …	X-RAY DIFFRACTION	1.48
5PAC	human factor VIIa in complex with …	X-RAY DIFFRACTION	1.5
5PAF	Crystal Structure of Factor VIIa in complex with …	X-RAY DIFFRACTION	1.5
4JZE	Structure of factor VIIA in complex with the inhibitor …	X-RAY DIFFRACTION	1.52
5PA9	Crystal Structure of Factor VIIa in complex with phenylmethanamine;hydrochloride	X-RAY DIFFRACTION	1.55
5PAU	Crystal Structure of Factor VIIa in complex with …	X-RAY DIFFRACTION	1.55
5PAK	Crystal Structure of Factor VIIa in complex with …	X-RAY DIFFRACTION	1.56
8QOD	CRYSTAL STRUCTURE OF FVIIA IN COMPLEX WITH A BENZAMIDINE-BASED INHIBITOR	X-RAY DIFFRACTION	1.57
5PAQ	Crystal Structure of Factor VIIa in complex with …	X-RAY DIFFRACTION	1.59
2BZ6	Orally available Factor7a inhibitor	X-RAY DIFFRACTION	1.6
5PAM	Crystal Structure of Factor VIIa in complex with …	X-RAY DIFFRACTION	1.6
5PAT	Crystal Structure of Factor VIIa in complex with …	X-RAY DIFFRACTION	1.6
5PAN	Crystal Structure of Factor VIIa in complex with …	X-RAY DIFFRACTION	1.62
5PAY	Crystal Structure of Factor VIIa in complex with …	X-RAY DIFFRACTION	1.66
1KLI	Cofactor-and substrate-assisted activation of factor VIIa	X-RAY DIFFRACTION	1.69
5PAJ	Crystal Structure of Factor VIIa in complex with 1-(1-aminoisoquinolin-6-yl)-3-benzylurea	X-RAY DIFFRACTION	1.7
2C4F	crystal structure of factor VII.stf complexed with pd0297121	X-RAY DIFFRACTION	1.72
3TH2	Mg2+ Is Required for Optimal Folding of the Gamma-Carboxyglutamic Acid (Gla) Domains of …	X-RAY DIFFRACTION	1.72
5L30	Factor VIIa in complex with the inhibitor …	X-RAY DIFFRACTION	1.73
5PAI	human factor VIIa in complex with …	X-RAY DIFFRACTION	1.73
5L2Z	Factor VIIa in complex with the inhibitor …	X-RAY DIFFRACTION	1.79

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P08709-F1	82.64	0.49

Antibody-complex structures (SAbDab)

3 antibodies co-crystallized with this protein: 8CN9, 9P0X, SUTACIMIG

Human Protein Atlas

Protein class: Enzymes, ENZYME proteins, Hydrolases, Peptidases, Serine-type peptidases, Predicted secreted proteins, Plasma proteins, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Biotech drugs, Human disease related genes

Protein evidence: Evidence at protein level

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (5)

Position	Role
404	charge relay system
113	important for s-112 for o-xylosylation
212–213	cleavage; by factor xa, factor xiia, factor ixa, or thrombin
253	charge relay system
302	charge relay system

Ligand- & substrate-binding residues (1)

Position	Role
398	substrate

Post-translational modifications (11)

Type	Positions
4-carboxyglutamate	66, 67, 74, 76, 79, 80, 85, 86, 89, 95
(3r)-3-hydroxyaspartate	123

Disulfide bonds (12)

Type	Positions
Disulfide bond	77–82, 110–121, 115–130, 132–141, 151–162, 158–172, 174–187, 195–322, 219–224, 238–254, 370–389, 400–428

Glycosylation sites (5)

Type	Positions
O-linked (glc…) serine	112
O-linked (xyl…) serine	112
O-linked (fuc) serine	120
N-linked (glcnac…) asparagine	205, 382

Mutagenesis-validated functional residues (2)

Position	Phenotype
112	complete loss of o-glycosylation and o-xylosylation by poglut1.
113	no effect on o-glycosylation by poglut1. drastic decrease in o-xylosylation.

Function

Pathways and Gene Ontology

Reactome pathways

5 curated (TAS) of 14; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

14 pathways:

ID	Pathway	Evidence
R-HSA-159740	Gamma-carboxylation of protein precursors	curated
R-HSA-9769735	Initiation of coagulation cascade	curated
R-HSA-9769739	Regulation of clotting cascade	curated
R-HSA-159782	Removal of aminoterminal propeptides from gamma-carboxylated proteins	curated
R-HSA-159763	Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus	curated
R-HSA-1368108	BMAL1:CLOCK,NPAS2 activates circadian expression	electronic
R-HSA-9909396	Circadian clock	—
R-HSA-163841	Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation	—
R-HSA-159854	Gamma-carboxylation, transport, and amino-terminal cleavage of proteins	—
R-HSA-109582	Hemostasis	—
R-HSA-392499	Metabolism of proteins	—
R-HSA-597592	Post-translational protein modification	—
R-HSA-140834		—
R-HSA-140877		—

MSigDB gene sets: 277 (showing top): GOBP_CIRCADIAN_RHYTHM, GOBP_PLATELET_DERIVED_GROWTH_FACTOR_RECEPTOR_SIGNALING_PATHWAY, MORF_RAGE, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_PROTEIN_ACTIVATION_CASCADE, MORF_FLT1, YAGI_AML_WITH_INV_16_TRANSLOCATION, GOBP_REGULATION_OF_WOUND_HEALING, GOBP_RESPONSE_TO_ESTRADIOL, GOBP_CELL_CHEMOTAXIS, GOBP_RESPONSE_TO_ACID_CHEMICAL, GOBP_INFLAMMATORY_RESPONSE, GOBP_REGULATION_OF_COAGULATION, STEARMAN_LUNG_CANCER_EARLY_VS_LATE_DN, GOBP_POSITIVE_REGULATION_OF_TOR_SIGNALING

GO Biological Process (30): response to hypoxia (GO:0001666), positive regulation of leukocyte chemotaxis (GO:0002690), blood coagulation (GO:0007596), circadian rhythm (GO:0007623), response to carbon dioxide (GO:0010037), positive regulation of platelet-derived growth factor receptor signaling pathway (GO:0010641), protein processing (GO:0016485), positive regulation of blood coagulation (GO:0030194), positive regulation of cell migration (GO:0030335), animal organ regeneration (GO:0031100), positive regulation of TOR signaling (GO:0032008), response to estradiol (GO:0032355), response to vitamin K (GO:0032571), response to genistein (GO:0033595), response to estrogen (GO:0043627), positive regulation of positive chemotaxis (GO:0050927), response to growth hormone (GO:0060416), response to cholesterol (GO:0070723), response to thyroxine (GO:0097068), response to Thyroid stimulating hormone (GO:1904400), response to 2,3,7,8-tetrachlorodibenzodioxine (GO:1904612), response to astaxanthin (GO:1905217), response to thyrotropin-releasing hormone (GO:1905225), proteolysis (GO:0006508), response to stress (GO:0006950), hemostasis (GO:0007599), response to hormone (GO:0009725), response to nutrient levels (GO:0031667), regulation of body fluid levels (GO:0050878), response to thyroid hormone (GO:0097066)

GO Molecular Function (8): serine-type endopeptidase activity (GO:0004252), signaling receptor binding (GO:0005102), calcium ion binding (GO:0005509), serine-type peptidase activity (GO:0008236), endopeptidase activity (GO:0004175), protein binding (GO:0005515), peptidase activity (GO:0008233), hydrolase activity (GO:0016787)

GO Cellular Component (7): extracellular region (GO:0005576), endoplasmic reticulum lumen (GO:0005788), Golgi lumen (GO:0005796), plasma membrane (GO:0005886), extracellular matrix (GO:0031012), vesicle (GO:0031982), serine-type peptidase complex (GO:1905286)

Reactome top-level categories

6 top-level categories:

Category	Pathways
Gamma-carboxylation, transport, and amino-terminal cleavage of proteins	3
Coagulation pathway	2
Circadian clock	1
Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation	1
Post-translational protein modification	1
Metabolism of proteins	1

GO top-level categories

showing 60 of 62 GO namespaces:

Category	Terms
response to oxygen-containing compound	3
positive regulation of chemotaxis	2
peptidase activity	2
intracellular organelle lumen	2
response to stress	1
response to decreased oxygen levels	1
positive regulation of leukocyte migration	1
regulation of leukocyte chemotaxis	1
leukocyte chemotaxis	1
hemostasis	1
wound healing	1
coagulation	1
rhythmic process	1
positive regulation of signal transduction	1
regulation of platelet-derived growth factor receptor signaling pathway	1
platelet-derived growth factor receptor signaling pathway	1
proteolysis	1
protein maturation	1
blood coagulation	1
regulation of blood coagulation	1
positive regulation of coagulation	1
positive regulation of wound healing	1
positive regulation of hemostasis	1
cell migration	1
regulation of cell migration	1
positive regulation of cell motility	1
regeneration	1
animal organ development	1
TOR signaling	1
regulation of TOR signaling	1
positive regulation of intracellular signal transduction	1
response to lipid	1
response to vitamin	1
response to ketone	1
response to hydroxyisoflavone	1
response to hormone	1
positive chemotaxis	1
regulation of positive chemotaxis	1
response to peptide hormone	1
response to sterol	1
response to alcohol	1
response to amino acid	1
response to thyroid hormone	1
response to L-phenylalanine derivative	1
response to glycoprotein	1
endopeptidase activity	1
serine-type peptidase activity	1
protein binding	1
metal ion binding	1
serine hydrolase activity	1
binding	1
hydrolase activity	1
catalytic activity, acting on a protein	1
catalytic activity	1
cellular anatomical structure	1
endoplasmic reticulum	1
Golgi apparatus	1
membrane	1
cell periphery	1
external encapsulating structure	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 8 of 46 annotations. The rest are phylogenetic / computational / electronic (IEA).

8 experimentally-supported GO terms:

GO term	NS	Evidence
blood coagulation	BP	direct assay
positive regulation of TOR signaling	BP	direct assay
positive regulation of leukocyte chemotaxis	BP	direct assay
positive regulation of platelet-derived growth factor receptor signaling pathway	BP	direct assay
positive regulation of positive chemotaxis	BP	direct assay
protein processing	BP	direct assay
extracellular matrix	CC	high-throughput assay
serine-type peptidase complex	CC	physical interaction

Protein interactions and networks

STRING

showing 15 of 945 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
F7	F3	P13726	978
F7	TFPI	P10646	942
F7	F8	P00451	942
F7	SERPINC1	P01008	871
F7	THBD	P07204	869
F7	GGCX	P38435	826
F7	VWF	P04275	793
F7	VKORC1	Q9BQB6	793
F7	GXYLT1	Q4G148	767
F7	GXYLT2	A0PJZ3	759
F7	SERPINE1	P05121	751
F7	SERPIND1	P05546	708
F7	CPB2	Q96IY4	699
F7	EGF	P01133	686
F7	MCFD2	Q8NI22	631

IntAct

Human interaction partners of F7 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

6 partners by confidence:

Partner	Interaction type	MIscore	Records
F3	direct interaction	0.880	5
L3	direct interaction	0.440	1
RCHY1	physical association	0.370	1
BECN1	association	0.350	1
C1QL1	association	0.350	1
IKBKG	physical association	0.000	1

BioGRID (19 interactions; top human partners by supporting records): F3 (Reconstituted Complex; 2 records), ALB (Affinity Capture-MS), C1QL1 (Affinity Capture-MS), CEP250 (Affinity Capture-MS), CEP76 (Affinity Capture-MS), CRELD2 (Affinity Capture-MS), DMWD (Affinity Capture-MS), F10 (Biochemical Activity), FUS (Affinity Capture-MS), HNRNPL (Affinity Capture-RNA), NMU (Affinity Capture-MS), RCHY1 (Two-hybrid), REV3L (Cross-Linking-MS (XL-MS)), UIMC1 (Affinity Capture-MS), USP49 (Affinity Capture-MS)

SIGNOR signaling

10 signaling interactions:

A	Effect	B	Mechanism
“Factor FVIIa:TF”	“up-regulates activity”	F7	cleavage
F9	“up-regulates activity”	F7	cleavage
F10	“up-regulates activity”	F7	cleavage
PROC	“down-regulates activity”	F7	cleavage
F2	“up-regulates activity”	F7
F7	“up-regulates activity”	F9	binding
F7	“up-regulates activity”	F10	binding
F7	“form complex”	“Factor FVIIa:TF”	binding
GGCX	“up-regulates activity”	F7	carboxylation
HPN	“up-regulates activity”	F7	cleavage

Protein complexes (CORUM) (3)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

3 complexes by size:

Complex	Subunits	Members
★ F3-F7-F10-TFPI complex	4	TFPI, F10, F3, F7
★ F3-F7-F10 complex	3	F10, F3, F7
★ F3-F7 complex	2	F3, F7

Disease & clinical

Genetic variants

Variant evidence for F7: 359 ClinVar records (71 pathogenic / likely pathogenic); 14 GWAS associations. Per-variant detail is on Sugi Variant.

ClinVar

359 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	25
Likely pathogenic	46
Uncertain significance	164
Likely benign	38
Benign	15

Top pathogenic / likely-pathogenic (15)

Showing the 15 best-reviewed of 71 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
12071	NM_019616.4(F7):c.1190C>T (p.Thr397Met)	Pathogenic	criteria provided, multiple submitters, no conflicts	3
1322860	NM_019616.4(F7):c.568C>T (p.Arg190Ter)	Pathogenic	criteria provided, multiple submitters, no conflicts	3
1691295	NM_019616.4(F7):c.225+1G>C	Pathogenic	criteria provided, multiple submitters, no conflicts	3
374352	NM_019616.4(F7):c.1219G>A (p.Ala407Thr)	Likely pathogenic	criteria provided, multiple submitters, no conflicts	5
626946	NM_000131.4(F7):c.-61T>G	Likely pathogenic	criteria provided, multiple submitters, no conflicts	4
626922	NM_019616.4(F7):c.-30A>C	Likely pathogenic	criteria provided, multiple submitters, no conflicts	3
627193	NM_019616.4(F7):c.961G>A (p.Gly321Ser)	Likely pathogenic	criteria provided, multiple submitters, no conflicts	3
3351690	NM_019616.4(F7):c.943C>T (p.Arg315Cys)	Likely pathogenic	criteria provided, multiple submitters, no conflicts	3
1315977	NM_019616.4(F7):c.400G>A (p.Gly134Ser)	Likely pathogenic	criteria provided, multiple submitters, no conflicts	2
1703834	NM_019616.4(F7):c.1206G>A (p.Trp402Ter)	Likely pathogenic	criteria provided, multiple submitters, no conflicts	2
2692371	NM_019616.4(F7):c.580G>C (p.Gly194Arg)	Likely pathogenic	criteria provided, multiple submitters, no conflicts	2
3381103	NM_019616.4(F7):c.365-2A>G	Likely pathogenic	criteria provided, multiple submitters, no conflicts	2
3575769	NM_019616.4(F7):c.1043G>A (p.Cys348Tyr)	Likely pathogenic	criteria provided, multiple submitters, no conflicts	2
3352537	NM_019616.4(F7):c.1008G>A (p.Met336Ile)	Pathogenic	criteria provided, single submitter	2
1098445	NM_019616.4(F7):c.394G>T (p.Glu132Ter)	Pathogenic	criteria provided, single submitter	1

Per-variant reference — Sugi Variant

Explore F7’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 26 predictions of 990):

Position(s)	Effect	Δscore	Sites
13:113117471–113117472	acceptor_loss	1.0000	4
13:113117597–113117598	donor_loss	1.0000	2
13:113118412	acceptor_loss	1.0000
13:113115658–113115659	acceptor_loss	0.9900	5
13:113117466	acceptor_gain	0.9900
13:113117472	acceptor_loss	0.9900
13:113117597–113117598	donor_loss	0.9900	3
13:113118411	acceptor_loss	0.9900	2
13:113110851–113110852	donor_loss	0.9800	6
13:113115659	acceptor_loss	0.9800

AlphaMissense

868 missense substitutions predicted likely pathogenic (of 2,883 scored), across 217 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
D302	8	0.970	0.992
D403	8	0.969	0.987
D398	8	0.927	0.982
H253	8	0.911	0.958
S404	8	0.894	0.980
S423	8	0.891	0.990
F388	8	0.890	0.988
N155	8	0.778	0.937
C130	7	0.987	0.993
C141	7	0.985	0.995
C115	7	0.984	0.994
C254	7	0.984	0.991
C400	7	0.984	0.994
C121	7	0.982	0.994
W344	7	0.982	0.997
C238	7	0.980	0.993
C132	7	0.979	0.987
C389	7	0.979	0.991
C322	7	0.978	0.989
C187	7	0.973	0.987

HPA cancer prognostics

RNA cancer specificity: Cancer enriched (Liver Hepatocellular Carcinoma)

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

1 prognostic cancer types:

Cancer	Prognostic	p-value
Kidney Chromophobe (TCGA)	favorable	3.4e-05

Disease associations

OMIM: gene MIM:613878 | disease phenotypes: MIM:227500, MIM:608446

GenCC curated gene-disease

2 curated gene-disease records:

Disease	Classification	Inheritance	Records
congenital factor VII deficiency	Definitive	Autosomal recessive	5
factor VII deficiency	Definitive	Autosomal recessive

ClinGen Gene-Disease Validity

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

1 validity classifications:

Disease	Classification	Inheritance
factor VII deficiency	Definitive	AR

Genomics England panels (PanelApp)

Clinical diagnostic gene panels including this gene (3 panels, 3 green/diagnostic-grade). Confidence: green = diagnostic, amber = moderate.

3 panels:

Panel	Rating
Bleeding and platelet disorders	green
Factor VII deficiency	green
Inherited bleeding disorders	green

Mondo (3): factor VII deficiency (MONDO:0002244), congenital factor VII deficiency (MONDO:0009211), myocardial infarction, susceptibility to (MONDO:0012039)

Orphanet (1): Congenital factor VII deficiency (Orphanet:327)

HPO phenotypes

18 phenotypes (HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000132	Menorrhagia
HP:0000138	Ovarian cyst
HP:0000225	Gingival bleeding
HP:0000421	Epistaxis
HP:0000978	Bruising susceptibility
HP:0001892	Abnormal bleeding
HP:0002170	Intracranial hemorrhage
HP:0002239	Gastrointestinal hemorrhage
HP:0004846	Prolonged bleeding after surgery
HP:0005261	Joint hemorrhage
HP:0006298	Prolonged bleeding after dental extraction
HP:0008151	Prolonged prothrombin time
HP:0008169	Reduced factor VII activity
HP:0010881	Abnormality of the umbilical cord
HP:0011463	Childhood onset
HP:0011891	Post-partum hemorrhage
HP:0012233	Intramuscular hematoma

GWAS associations

14 associations:

Study	Trait	p-value
GCST007401_30	Factor VII activity	0.000000e+00
GCST007401_31	Factor VII activity	0.000000e+00
GCST007401_8	Factor VII activity	0.000000e+00
GCST007402_1	Factor VII activity or levels	0.000000e+00
GCST000625_1	Factor VII levels	9e-256
GCST006017_8	Prothrombin time	5e-246
GCST006585_2129	Blood protein levels	2e-191
GCST007401_32	Factor VII activity	2e-58
GCST001573_1	Prothrombin time	4e-56
GCST007401_29	Factor VII activity	6e-38
GCST007401_27	Factor VII activity	4e-22
GCST007401_28	Factor VII activity	2e-19
GCST000082_1	Factor VII	5e-16
GCST008103_61	Bipolar disorder	1e-6

EFO canonical traits (from GWAS)

2 canonical traits:

EFO ID	Trait name
EFO:0004619	factor VII measurement
EFO:0008390	prothrombin time measurement

MeSH disease descriptors

1 disease descriptors:

Descriptor	Name	Tree numbers
D005168	Factor VII Deficiency	C15.378.100.100.310; C15.378.100.141.310; C15.378.463.310; C16.320.099.310

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (4): CHEMBL2095194 (PROTEIN COMPLEX), CHEMBL2111412 (SELECTIVITY GROUP), CHEMBL2111477 (SELECTIVITY GROUP), CHEMBL3991 (SINGLE PROTEIN)

Drugs by curated mechanism of action (ChEMBL)

Drugs whose curated ChEMBL mechanism of action targets the F7 protein itself — single-protein targets only (drugs acting on a protein family or complex that merely includes it are excluded). Includes antibodies and oligonucleotides that bioactivity screening does not capture.

6 curated-mechanism drugs:

Drug	Modality	Max phase
COAGULATION FACTOR VII HUMAN	Protein	4
EPTACOG ALFA (ACTIVATED)	Protein	4
EPTACOG BETA (ACTIVATED)	Unknown	4
PROTHROMBIN COMPLEX CONCENTRATE	Protein	3
EPTACOG ALFA PEGOL (ACTIVATED)	Unknown	2
PCI-27483	Small molecule	2

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,374,508 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

8 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL266349	MELAGATRAN	4	5,456
CHEMBL1140	NIACINAMIDE	4	233,296
CHEMBL464982	GAMOLENIC ACID	3	26,834
CHEMBL460026	ICOSAPENT	3	60,919
CHEMBL4112929	MILVEXIAN	3	142
CHEMBL465183	DIHOMO-GAMMA-LINOLENIC ACID	2	2,109
CHEMBL267476	LINOLEIC ACID	2	325,752
CHEMBL8659	OLEIC ACID	2	720,000

PharmGKB: 1 entry (CPIC guideline: no)

PharmGKB variant annotations

Per-publication pharmacogenomic findings for this gene (significant associations).

5 published findings:

Variant	Drug(s)	Category	Finding	PMID
rs6046	warfarin	Efficacy	Genotype AA is associated with increased sen sitivity to warfarin during induction when treated with warfarin as compared to genotypes AG + GG.	PMID:22071881
rs6046	warfarin	Toxicity	Genotype AA is associated with increased risk of over-anticoagulation when treated with warfarin as compared to genotypes AG + GG.	PMID:22071881
rs510317	warfarin	Dosage	Genotypes AA + AG are associated with increased dose of warfarin as compared to genotype GG.	PMID:19387626
rs510335	warfarin	Dosage	Genotypes GT + TT are associated with decreased warfarin dose when treated with warfarin as compared to genotype GG.	PMID:15590403
rs510317	warfarin	Dosage	Genotype GG is associated with decreased warfarin dose when treated with warfarin as compared to genotype AA.	PMID:14656880

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — S1: Chymotrypsin

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
compound 1 [PMID: 16650987]	Inhibition	9.0	pKi
compound 11 [PMID: 16413183]	Inhibition	7.0	pKi

Binding affinities (BindingDB)

892 measured of 1058 human assays (1068 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
(15R)-2-[(1-aminoisoquinolin-6-yl)amino]-8-fluoro-4,15,17-trimethyl-7-[(3S)-oxolan-3-yl]oxy-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	0.02 nM	US-9174974: Macrocyclic factor VIIa inhibitors
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-8-fluoro-4,15,17-trimethyl-7-[(3R)-oxolan-3-yl]oxy-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	0.05 nM	US-9174974: Macrocyclic factor VIIa inhibitors
CHEMBL3956096	KI	0.06 nM
2-(3’-Amino-5-chloro-2-hydroxy-biphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine	KI	0.078 nM
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,17-trimethyl-7-[1-(2H-tetrazol-5-yl)cyclopropyl]-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	0.12 nM	US-9174974: Macrocyclic factor VIIa inhibitors
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-8-fluoro-7-[(2S)-1-hydroxypropan-2-yl]oxy-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	0.14 nM	US-9174974: Macrocyclic factor VIIa inhibitors
(2R,15R)-2-[(1-amino-7-fluoroisoquinolin-6-yl)amino]-8-fluoro-4,15,17-trimethyl-7-propan-2-ylsulfonyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	0.14 nM	US-9174974: Macrocyclic factor VIIa inhibitors
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-8-fluoro-4,15,17-trimethyl-7-[2-(2-oxopyrrolidin-1-yl)ethoxy]-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	0.14 nM	US-9174974: Macrocyclic factor VIIa inhibitors
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-8-fluoro-7-[(2S)-1-methoxypropan-2-yl]oxy-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	0.14 nM	US-9174974: Macrocyclic factor VIIa inhibitors
CHEMBL3900166	KI	0.14 nM
1-[3-(Aminomethyl)phenyl]-N-[3-fluoro-2-(methylsulfonyl)-[1,1-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide	KI	0.15 nM
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-7-(1,3-difluoropropan-2-yloxy)-8-fluoro-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	0.15 nM	US-9174974: Macrocyclic factor VIIa inhibitors
(2R,15R)-2-[(1-amino-7-fluoroisoquinolin-6-yl)amino]-7-cyclopropylsulfonyl-8-fluoro-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	0.17 nM	US-9174974: Macrocyclic factor VIIa inhibitors
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-8-fluoro-7-[(2R)-1-hydroxypropan-2-yl]oxy-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	0.17 nM	US-9174974: Macrocyclic factor VIIa inhibitors
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-7-cyclopropylsulfonyl-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	0.17 nM	US-9174974: Macrocyclic factor VIIa inhibitors
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-8-fluoro-7-(3-methoxypropoxy)-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	0.2 nM	US-9174974: Macrocyclic factor VIIa inhibitors
CHEMBL3984725	KI	0.22 nM
(2R,15R)-2-[(1-amino-7-fluoroisoquinolin-6-yl)amino]-7-cyclopropylsulfonyl-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	0.23 nM	US-9174974: Macrocyclic factor VIIa inhibitors
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-8-fluoro-7-[(3R,4S)-4-hydroxyoxolan-3-yl]oxy-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	0.23 nM	US-9174974: Macrocyclic factor VIIa inhibitors
CHEMBL3898956	KI	0.24 nM
(2R,15R)-2-[(1-amino-7-fluoroisoquinolin-6-yl)amino]-7-cyclopropylsulfonyl-19-fluoro-17-methoxy-4,15-dimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	0.25 nM	US-9174974: Macrocyclic factor VIIa inhibitors
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-7-cyclopropylsulfonyl-15-(fluoromethyl)-4,17-dimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	0.28 nM	US-9174974: Macrocyclic factor VIIa inhibitors
CHEMBL3978562	KI	0.28 nM
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-N-ethyl-4,15,17-trimethyl-3,12-dioxo-N-(1,3-thiazol-2-ylmethyl)-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-7-carboxamide	KI	0.3 nM	US-9174974: Macrocyclic factor VIIa inhibitors
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-7-tert-butylsulfonyl-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	0.31 nM	US-9174974: Macrocyclic factor VIIa inhibitors
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-7-[(2R)-2-cyclopropyl-2-hydroxyethoxy]-8-fluoro-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	0.34 nM	US-9174974: Macrocyclic factor VIIa inhibitors
(2R)-N-[(3-aminobenzene)sulfonyl]-2-[(4-carbamimidoyl-3-hydroxyphenyl)amino]-2-(3,5-diethoxy-2-fluorophenyl)acetamide	KI	0.35 nM
(2R,15R)-2-[(1-amino-8-fluoroisoquinolin-6-yl)amino]-8-fluoro-4,15,17-trimethyl-7-propan-2-ylsulfonyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	0.36 nM	US-9174974: Macrocyclic factor VIIa inhibitors
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-8-fluoro-7-[(1-isocyanocyclopropyl)methoxy]-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	0.44 nM	US-9174974: Macrocyclic factor VIIa inhibitors
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-8-fluoro-7-[(2S)-2-hydroxypropoxy]-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	0.46 nM	US-9174974: Macrocyclic factor VIIa inhibitors
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-7-cyclopropylsulfonyl-15-(difluoromethyl)-4,17-dimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	0.5 nM	US-9174974: Macrocyclic factor VIIa inhibitors
1-[(2R,15R)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-4,15,17-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaen-7-yl]cyclopropane-1-carboxylic acid	KI	0.55 nM	US-9174974: Macrocyclic factor VIIa inhibitors
CHEMBL3898371	KI	0.55 nM
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-N,N-diethyl-4,15,17-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-7-carboxamide	KI	0.57 nM	US-9174974: Macrocyclic factor VIIa inhibitors
(2R)-2-[(2R,15R)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-4,15,17-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaen-7-yl]butanoic acid	KI	0.61 nM	US-9174974: Macrocyclic factor VIIa inhibitors
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-7-diethoxyphosphoryl-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	0.62 nM	US-9174974: Macrocyclic factor VIIa inhibitors
CHEMBL2409219	KI	0.62 nM
(2R,15R)-2-[(1-amino-8-fluoroisoquinolin-6-yl)amino]-7-cyclopropylsulfonyl-8-fluoro-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	0.66 nM	US-9174974: Macrocyclic factor VIIa inhibitors
CHEMBL3967204	KI	0.72 nM
(2R)-2-[(2R,15R)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-4,15,17-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaen-7-yl]-4,4-difluorobutanoic acid	KI	0.9 nM	US-9174974: Macrocyclic factor VIIa inhibitors
(2R,15R)-2-[(1-amino-8-fluoroisoquinolin-6-yl)amino]-7-cyclopropylsulfonyl-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	1 nM	US-9174974: Macrocyclic factor VIIa inhibitors
Biotinylated E-76 peptide analogue	IC50	1 nM
ALCDNPRIDRWYCQFVEG peptide analogue	IC50	1 nM
2-[5-(5-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2’-dihydroxy-5’-ureidomethyl-biphenyl-3-yl]-succinic acid	KI	1 nM
2-[5-(5-carbamimidoyl-1H-indol-2-yl)-6-hydroxy-3’-nitro-biphenyl-3-yl]-succinic acid	KI	1 nM
CHEMBL3909009	KI	1 nM
CHEMBL2431588	KI	1 nM
(2R)-2-[(1-aminoisoquinolin-6-yl)amino]-7-ethylsulfonyl-17,20-dimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(19),6,8,10(21),16(20),17-hexaene-3,12-dione	KI	1.1 nM	US-9174974: Macrocyclic factor VIIa inhibitors
ALCDNPRIDRWYCQFVEG peptide analogue	IC50	1.1 nM
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-7-(azetidine-1-carbonyl)-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	KI	1.2 nM	US-9174974: Macrocyclic factor VIIa inhibitors

ChEMBL bioactivities

936 potent at pChembl≥5 of 1030 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
11.00	IC50	0.01	nM	CHEMBL505189
11.00	IC50	0.01	nM	CHEMBL505190
10.96	IC50	0.011	nM	CHEMBL484616
10.96	IC50	0.011	nM	CHEMBL506771
10.96	IC50	0.011	nM	CHEMBL526504
10.92	IC50	0.012	nM	CHEMBL523251
10.89	IC50	0.013	nM	CHEMBL520364
10.85	IC50	0.014	nM	CHEMBL506772
10.70	Ki	0.02	nM	CHEMBL3930738
10.70	IC50	0.02	nM	CHEMBL524370
10.68	IC50	0.021	nM	CHEMBL524732
10.62	IC50	0.024	nM	CHEMBL503584
10.60	IC50	0.025	nM	CHEMBL487956
10.54	IC50	0.029	nM	CHEMBL507281
10.52	IC50	0.03	nM	CHEMBL488778
10.48	IC50	0.033	nM	CHEMBL507020
10.47	IC50	0.034	nM	CHEMBL484615
10.44	IC50	0.036	nM	CHEMBL499632
10.38	IC50	0.042	nM	CHEMBL487955
10.35	IC50	0.045	nM	CHEMBL505720
10.30	Ki	0.05	nM	CHEMBL3986081
10.28	IC50	0.052	nM	CHEMBL497067
10.22	Ki	0.06	nM	CHEMBL3956096
10.22	IC50	0.06	nM	CHEMBL498047
10.17	IC50	0.067	nM	CHEMBL519886
10.12	IC50	0.076	nM	CHEMBL527118
10.11	Ki	0.078	nM	CHEMBL73737
10.04	IC50	0.092	nM	CHEMBL500948
10.01	IC50	0.097	nM	CHEMBL485705
10.01	IC50	0.098	nM	CHEMBL525274
9.98	IC50	0.104	nM	CHEMBL524548
9.92	Ki	0.12	nM	CHEMBL3902759
9.92	IC50	0.12	nM	CHEMBL224485
9.89	IC50	0.13	nM	CHEMBL526193
9.85	Ki	0.14	nM	CHEMBL3900166
9.85	Ki	0.14	nM	CHEMBL3977297
9.85	Ki	0.14	nM	CHEMBL3967595
9.85	Ki	0.14	nM	CHEMBL3903215
9.85	Ki	0.14	nM	CHEMBL3969432
9.82	Ki	0.15	nM	CHEMBL3906646
9.80	Ki	0.16	nM	CHEMBL3891120
9.77	Ki	0.17	nM	CHEMBL3961226
9.77	Ki	0.17	nM	CHEMBL3915633
9.77	Ki	0.17	nM	CHEMBL3891120
9.72	IC50	0.19	nM	CHEMBL499829
9.70	Ki	0.2	nM	CHEMBL3920165
9.66	Ki	0.22	nM	CHEMBL3984725
9.64	Ki	0.23	nM	CHEMBL3901391
9.64	Ki	0.23	nM	CHEMBL3892246
9.64	IC50	0.231	nM	CHEMBL504391

PubChem BioAssay actives

1119 with measured affinity, of 1900 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
135986123	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-methoxyphenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
2-[4-[4-(aminomethyl)thiophen-3-yl]-2-[(4-carbamimidoylphenyl)carbamoyl]phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-prop-1-ynylphenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-(thiophen-2-ylmethyl)phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-(furan-3-yl)phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-[3-(hydroxymethyl)furan-2-yl]phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-thiophen-2-ylphenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-thiophen-3-ylphenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-ethenylphenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-[2-(hydroxymethyl)thiophen-3-yl]phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-prop-2-enylphenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-(1H-pyrrol-2-yl)phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-(3-hydroxyprop-1-en-2-yl)phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-(3-methylbut-2-enyl)phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-(4-hydroxybut-1-en-2-yl)phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-(furan-2-yl)phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-[4-(hydroxymethyl)thiophen-3-yl]phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
2-[4-[4-(azidomethyl)thiophen-3-yl]-2-[(4-carbamimidoylphenyl)carbamoyl]phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-[2-(hydroxymethyl)furan-3-yl]phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-[4-(hydroxymethyl)furan-3-yl]phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
2-[4-benzyl-2-[(4-carbamimidoylphenyl)carbamoyl]phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-ethynylphenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-prop-1-en-2-ylphenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
2-[4-[(Z)-but-2-enyl]-2-[(4-carbamimidoylphenyl)carbamoyl]phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	<0.0001	uM
1-[(2R,15R)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-4,15,17-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaen-7-yl]cyclobutane-1-carboxylic acid	1316610: Inhibition of recombinant human TF-factor 7a using factor 10 as substrate at 37 degC	ki	0.0001	uM
1-[(2R,15R)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-4,15,17-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaen-7-yl]cyclohexane-1-carboxylic acid	1316610: Inhibition of recombinant human TF-factor 7a using factor 10 as substrate at 37 degC	ki	0.0001	uM
2-[3-(3-aminophenyl)-5-chloro-2-hydroxyphenyl]-3H-benzimidazole-5-carboximidamide	72364: Binding affinity for factor VIIa/TF	ki	0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-phenylphenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-(1,3-thiazol-2-yl)phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-[(1Z)-3-methylbuta-1,3-dienyl]phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-[(E)-3-hydroxyprop-1-enyl]phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-propylphenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	0.0001	uM
2-[4-(azidomethyl)-2-[(4-carbamimidoylphenyl)carbamoyl]phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-(1-methylpyrrol-2-yl)phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-hydroxyphenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	0.0001	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-ethylphenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	0.0001	uM
(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-7-cyclopropylsulfonyl-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	1315769: Inhibition of full-length human TF/recombinant human factor 7a assessed as decrease in conversion of factor 10 to factor 10a by measuring S2765 hydrolysis after 15 mins	ki	0.0002	uM
(2R,15R)-2-[(1-amino-7-fluoroisoquinolin-6-yl)amino]-7-cyclopropylsulfonyl-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	1315769: Inhibition of full-length human TF/recombinant human factor 7a assessed as decrease in conversion of factor 10 to factor 10a by measuring S2765 hydrolysis after 15 mins	ki	0.0002	uM
1-[(2R,15R)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-4,15,17-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaen-7-yl]cyclopentane-1-carboxylic acid	1316610: Inhibition of recombinant human TF-factor 7a using factor 10 as substrate at 37 degC	ki	0.0002	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-pyridin-4-ylphenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	0.0002	uM
3-[3-[(4-carbamimidoylphenyl)carbamoyl]-4-[2-carboxy-4-(2-methylpropylcarbamoyl)phenyl]phenyl]thiophene-2-carboxylic acid	397857: Inhibition of tissue factor/factor 7a	ic50	0.0002	uM
(5R,11R)-11-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-16-cyclopropylsulfonyl-7-(2,2-difluoroethoxy)-5,13-dimethyl-2,13-diazatricyclo[13.3.1.16,10]icosa-1(19),6,8,10(20),15,17-hexaene-3,12-dione	1331371: Inhibition of recombinant human factor-7a/TF using S2288 as substrate measured after 60 mins at 37 degC	ki	0.0002	uM
[(2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,15,17-trimethyl-3,12-dioxo-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaen-7-yl]-ethoxyphosphinic acid	1315769: Inhibition of full-length human TF/recombinant human factor 7a assessed as decrease in conversion of factor 10 to factor 10a by measuring S2765 hydrolysis after 15 mins	ki	0.0003	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-[3-(hydroxymethyl)thiophen-2-yl]phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	0.0003	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-(3-hydroxyprop-1-ynyl)phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	0.0003	uM
(2R)-N-(3-aminophenyl)sulfonyl-2-(4-carbamimidoyl-3-hydroxyanilino)-2-(3,5-diethoxy-2-fluorophenyl)acetamide	1195253: Inhibition of human factor 7a	ki	0.0003	uM
(2R,15R)-2-[(1-amino-4-fluoroisoquinolin-6-yl)amino]-7-cyclopropylsulfonyl-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.16,10]henicosa-1(18),6,8,10(21),16,19-hexaene-3,12-dione	1315769: Inhibition of full-length human TF/recombinant human factor 7a assessed as decrease in conversion of factor 10 to factor 10a by measuring S2765 hydrolysis after 15 mins	ki	0.0004	uM
2-[2-[(4-carbamimidoylphenyl)carbamoyl]-4-(4-hydroxybut-1-ynyl)phenyl]-5-(2-methylpropylcarbamoyl)benzoic acid	397857: Inhibition of tissue factor/factor 7a	ic50	0.0005	uM

CTD chemical–gene interactions

56 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Ethinyl Estradiol	affects binding, increases expression, affects cotreatment, decreases expression, affects reaction	6
Benzo(a)pyrene	affects methylation, decreases expression, decreases methylation	4
Gestodene	affects cotreatment, increases expression, affects reaction	3
Warfarin	increases reaction, affects response to substance, decreases expression	3
Aflatoxin B1	affects methylation, decreases expression, decreases methylation	3
ethinyl estradiol-desogestrel combination	increases expression, affects reaction	2
Contraceptives, Oral	increases activity, increases expression	2
Valproic Acid	affects expression, decreases expression	2
Cyclosporine	decreases expression, increases expression	2
Levonorgestrel	affects cotreatment, decreases expression, increases expression	2
methyleugenol	decreases expression	1
propionaldehyde	decreases expression	1
bisphenol A	increases expression	1
antibiotic G 418	increases activity, increases expression	1
ethyl-p-hydroxybenzoate	decreases expression	1
norgestimate	affects cotreatment, increases expression	1
sodium arsenite	decreases expression	1
butyraldehyde	decreases expression	1
perfluorooctanoic acid	decreases expression	1
dienogest	increases expression, affects cotreatment	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
CycloProvera	decreases expression	1
CMF protocol	decreases expression	1
pentanal	decreases expression	1
norgestimate, ethinyl estradiol drug combination	increases expression	1
estradiol, norethindrone drug combination	decreases expression	1
estradiol valerate-dienogest	affects cotreatment, increases expression	1
abrine	decreases expression	1
NuvaRing	increases expression	1

ChEMBL screening assays

255 unique, capped per target: 237 binding, 17 functional, 1 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1005944	Binding	Inhibition of human tissue factor/factor 7a	Novel 3-carboxamide-coumarins as potent and selective FXIIa inhibitors. — *J Med Chem*
CHEMBL855827	Functional	Anticoagulant activity in human plasma measured as prothrombin time	Preparation of 1-(3-aminobenzo[d]isoxazol-5-yl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective, and efficacious inhibitors of coagulation factor Xa. — *Bioorg Med Chem Lett*
CHEMBL4621401	ADMET	Inhibition of human F7a using fluorescent peptide as substrate by florescence assay	Structure-Based Design and Preclinical Characterization of Selective and Orally Bioavailable Factor XIa Inhibitors: Demonstrating the Power of an Integrated S1 Protease Family Approach. — *J Med Chem*

Cellosaurus cell lines

5 cell lines: 2 transformed cell line, 1 induced pluripotent stem cell, 1 cancer cell line, 1 telomerase immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A1ND	YCMi002-A	Induced pluripotent stem cell	Female
CVCL_E3FM	HEK293T-FVII	Transformed cell line	Female
CVCL_E3FN	HepG2-FVII	Cancer cell line	Male
CVCL_WG88	HEK293-Nrf2 clone 2-FVII	Transformed cell line	Female
CVCL_XY59	imHC-FVII	Telomerase immortalized cell line	Sex unspecified

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 169 trials:

NCT	Phase	Status	Title
NCT00707772	Phase 4	COMPLETED	Pegasys® Plus Ribavirin in Hemophilic Patients With Hepatitis C Virus Infection
NCT04108260	Phase 4	UNKNOWN	The Effectiveness of Recombinant Coagulation Factor IX With Recombinant Albumin (rIX-FP) in Severe Hemophilia B Patients
NCT05728528	Phase 4	COMPLETED	Impact of Moderate Intensity Physical Activities on PK-guided EHL FVIII Concentrates Prophylaxis Severe HA Patients
NCT06752850	Phase 4	ACTIVE_NOT_RECRUITING	A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemophilia A on Efanesoctocog Alfa Prophylaxis
NCT07406139	Phase 4	RECRUITING	PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）
NCT03079063	Phase 3	COMPLETED	Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency
NCT00606060	Phase 3	COMPLETED	BAY14-2222 Continuous Infusion in Surgeries
NCT02306694	Phase 3	COMPLETED	Prospective Biomarkers of Bone Metabolism in Hemophilia A
NCT02548143	Phase 3	COMPLETED	LR769 in Congenital Hemophilia Patients With Inhibitors Undergoing Elective Surgery or Invasive Procedures
NCT03549871	Phase 3	COMPLETED	A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis
NCT03754790	Phase 3	ACTIVE_NOT_RECRUITING	Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
NCT03974113	Phase 3	COMPLETED	Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B
NCT05662319	Phase 3	ACTIVE_NOT_RECRUITING	A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia
NCT05695391	Phase 3	TERMINATED	Safety and Efficacy of FVIIa to Prevent Excessive Bleeding in Hemophilia Patients With Inhibitors Undergoing Major Surgery
NCT06922045	Phase 3	ACTIVE_NOT_RECRUITING	Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients
NCT07285460	Phase 3	RECRUITING	A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B
NCT07347249	Phase 2	RECRUITING	A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII Deficiency
NCT07711158	Phase 2	NOT_YET_RECRUITING	A Phase II Exploratory Study of SR604 Injection Evaluating the Safety and Efficacy in the Treatment of Congenital Coagulation Factor VII Deficiency
NCT00055341	Phase 2	COMPLETED	Treatment of Hepatitis C in Hemophilic Patients With HIV
NCT02586012	Phase 2	TERMINATED	Weight-based Dosing in Hemophilia A
NCT05421429	Phase 2	COMPLETED	KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia
NCT05619926	Phase 2	COMPLETED	Safety and Efficacy of STSP-0601 in Adult Patients With Hemophilia A or B Without Inhibitor
NCT06289166	Phase 2	COMPLETED	Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor
NCT05651061	Phase 1	COMPLETED	A Phase I of SS109 in Hemophilia A or and B With Inhibitors
NCT06349473	Phase 1	RECRUITING	A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
NCT01191372	Phase 1	TERMINATED	First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients
NCT01704521	Phase 1	COMPLETED	Viral Kinetics in HCV Clearance in Subjects With Hemophilia
NCT01708564	Phase 1	COMPLETED	A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B
NCT02060305	Phase 1	TERMINATED	Intra-articular Bevacizumab for Recurrent Hemarthroses at Target Joints With Chronic Hemophilic Synovitis
NCT02108132	Phase 1	UNKNOWN	Allogenic Bone Marrow Derived Mesenchymal Stem Cell Therapy in Cases of Hemophilia
NCT03855696	Phase 1	COMPLETED	A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia Patients
NCT03996486	Phase 1	WITHDRAWN	Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia
NCT04747964	Phase 1	COMPLETED	A Safety Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor
NCT04878731	Phase 1	COMPLETED	Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia
NCT05493631	Phase 1	COMPLETED	A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient
NCT04548791	Phase 1/2	TERMINATED	Study of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders
NCT07644832	Phase 1/2	RECRUITING	An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
NCT01269138	Not specified	COMPLETED	Treatment of Inherited Factor VII Deficiency
NCT03372993	Not specified	COMPLETED	Prospective, Non-interventional Study to Evaluate Immunogenicity of AryoSeven
NCT03655223	Not specified	ACTIVE_NOT_RECRUITING	Early Check: Expanded Screening in Newborns
NCT06938542	Not specified	ENROLLING_BY_INVITATION	Palliative Care Needs of Children With Rare Diseases and Their Families
NCT05027230	Phase 1/2	COMPLETED	A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor
NCT05920512	Phase 1/2	UNKNOWN	Combination Regimen With Sodium Valproate for Severe Hemophilia: a Single-arm, Phase 1, Pilot Trial.
NCT06010953	Phase 1/2	COMPLETED	SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment
NCT03272568	Early Phase 1	COMPLETED	Extended Half Life Factor (EHF) Products For Heavy Menstrual Bleeding in Hemophilia Carriers
NCT06345833	Early Phase 1	WITHDRAWN	Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded Study
NCT00127543	Not specified	WITHDRAWN	Kid Cards: Teaching Kids About Medicines
NCT00324493	Not specified	UNKNOWN	Musculoskeletal Function in Hemophilia
NCT00340548	Not specified	TERMINATED	Host Genetic Factors Influencing HIV1 and HCV Viral Loads and AIDS Clinical Progression in a Hemophilia Cohort (HGDS-3)
NCT00344435	Not specified	COMPLETED	Genetic Susceptibility to Factor VIII Inhibitors
NCT00640289	Not specified	COMPLETED	Clinical Trial of Factor XIII (FXIII) Concentrate
NCT00697385	Not specified	COMPLETED	The Use of Cyclokapron for Treatment and Management of Women With Bleeding Disorders
NCT00798499	Not specified	COMPLETED	A Feasibility Study to Collect Data in Patients With Haemophilia
NCT00927992	Not specified	COMPLETED	Study Evaluating Liver Transplantation in Haemophilia Patients in Spain
NCT01000844	Not specified	COMPLETED	Joint Outcome Study Continuation for Children With Severe Factor VIII Deficiency
NCT01029808	Not specified	COMPLETED	Bleeding Symptoms of Carriers of Hemophilia A and B
NCT01105923	Not specified	UNKNOWN	Study of an Intervention to Improve Problem List Accuracy and Use
NCT01232634	Not specified	COMPLETED	Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles
NCT01431326	Not specified	COMPLETED	Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
NCT01817868	Not specified	COMPLETED	Comparison of Efficacy, Safety and Costs of Recombinant FVIII Products Between On-demand and Secondary Prophylaxis Groups in Haemophilia A Patients

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for F7 across ~30M SureChEMBL compounds — explore on Sugi Predict.